𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A 6-month, open-label study of memantine in patients with frontotemporal dementia

✍ Scribed by Janine Diehl-Schmid; Hans Förstl; Robert Perneczky; Corina Pohl; Alexander Kurz

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
72 KB
Volume
23
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To evaluate safety and effects on cognition and behavior of memantine 20 mg/day in the treatment of patients with frontotemporal dementia (FTD).

Methods

This was a single‐center, 6‐month, open, uncontrolled study. Sixteen outpatients with a diagnosis of FTD were enrolled.

Results

On the CIBIC plus 26 weeks after baseline four of the 16 patients were minimally improved, four were unchanged, seven were minimally worse and one patient was moderately worse. Neither the Neuropsychiatric Inventory nor the Frontal Behavioral Inventory demonstrated statistically significant differences in behavior between baseline and final visit. There was an increase in the total Alzheimer's Disease Assessment Scale score, reflecting a decline in cognitive performance. Executive functions as well as activities of daily living and extrapyramidal motor symptoms (EPMS) remained unchanged during the trial.

Conclusion

The number of patients was small, so that the evidence given by statistical tests is limited. Thus, the present study can only show trends regarding drug effects. As memantine is well‐tolerated, further randomized and controlled studies should be conducted to evaluate drug efficacy. Copyright © 2008 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Safety and efficacy of long-acting injec
Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients
✍ Swapna Verma; Mythily Subramaniam; Edimansyah Abdin; Kang Sim; Alex Su; Nelson L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract The study aimed to evaluate the efficacy of long‐acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders. Twenty‐five patients enrolled in this 6‐month open labelled study. They were switched from their current antipsychotic to LAR without a prior or

Controlled withdrawal of pramipexole aft
Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
✍ Claudia Trenkwalder; Karin Stiasny-Kolster; Andreas Kupsch; Wolfgang H. Oertel; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

## Abstract Although dopamine agonists are becoming first‐line therapy for restless legs syndrome (RLS), few reports describe treatment periods exceeding 12 weeks. Here, 150 RLS patients who had responded to pramipexole during a 6‐month run‐in period (mean dose, 0.50 mg) were randomly assigned to r

Safety and tolerability of rivastigmine
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
✍ Jason T. Olin; Vinod Bhatnagar; Patricio Reyes; Barbara Koumaras; Xiangyi Meng; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 2 views

## Abstract ## Objective Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild‐to‐moderate Alzheimer's disease (AD) and Parkinson's disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects an